Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 51 Small Cell Lung Carcinoma 23 Breast Neoplasms 18 Sarcoma 17 Lung Neoplasms 10 Carcinoma, Hepatocellular 10 Esophageal Squamous Cell Carcinoma 9 Stomach Neoplasms 8 Neoplasms 8 Triple Negative Breast Neoplasms 7 Ovarian Neoplasms 7 Nasopharyngeal Carcinoma 7 Thyroid Neoplasms 6 Neoplasm Metastasis 6 Esophageal Neoplasms 6 Pancreatic Neoplasms 5 NSCLC 5 Colorectal Neoplasms 5 Carcinoma 5 Uterine Cervical Neoplasms 4 Pheochromocytoma 4 Endometrial Neoplasms 4 Carcinoma, Renal Cell 4 Carcinoma, Ovarian Epithelial 4 Recurrence 3 Paraganglioma 3 Non-squamous Non-small Cell Lung Cancer 3 Glioma 3 Fallopian Tube Neoplasms 3 Cholangiocarcinoma 3

Interventions

Ibandronic Acid 8 Gemcitabine 8 Doxorubicin 6 Cyclophosphamide 6 Zoledronic Acid 5 Radiation 4 Nivolumab 4 Irinotecan 4 pembrolizumab 3 Vincristine 3 Temozolomide 3 Magnetic Resonance Spectroscopy 3 Ipilimumab 3 Docetaxel 3 Denosumab 3 Cisplatin 3 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 3 regorafenib 2 pegfilgrastim 2 Tranexamic Acid 2 Trabectedin 2 Surveys and Questionnaires 2 Sunitinib 2 Standard of Care 2 Radiotherapy, Intensity-Modulated 2 Radiotherapy 2 Radiosurgery 2 Quality of Life 2 Proton Therapy 2 Observation 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Bone Neoplasms × anlotinib × Clear all

NCT03527888 2019-05-21

Study of Anlotinib in Patients With Primary Malignant Bone Tumors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Unknown

Bone Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡